Cadmium Compliance Plan — 29 CFR 1910.1027 / 1926.1127
Written compliance program for cadmium exposure — NiCd battery manufacturing, electroplating, pigment production, cadmium-containing welding/brazing/soldering. PEL 5 µg/m³, Action Level 2.5 µg/m³. Includes the biomonitoring program (cadmium in urine, cadmium in blood, β2-microglobulin).
When this template is required
29 CFR 1910.1027 applies to all occupational exposure to cadmium outside construction (construction is covered by 29 CFR 1926.63). A written compliance program is required where the PEL is exceeded (1910.1027(f)(2)(i)). Typical settings: battery manufacturing (NiCd), electroplating, pigment production, brazing and welding with cadmium-bearing alloys, soldering. PEL: 5 µg/m³ 8-hour TWA; Action Level: 2.5 µg/m³. Cadmium is a known carcinogen with kidney toxicity at chronic low-level exposure.
Why this template
Triple biomonitoring
1910.1027(l) requires three biomonitoring tests for cadmium-exposed workers: CdU (cadmium in urine — body burden), CdB (cadmium in blood — recent exposure), β2-M (β2-microglobulin in urine — early kidney effect). The plan documents all three with action thresholds.
Carcinogen + kidney toxicity
Cadmium is classified as a Group 1 carcinogen by IARC (lung cancer). It also causes kidney damage at chronic low-level exposure (β2-M elevation is the early indicator). The plan addresses both hazards.
Welding/brazing trigger
Brazing with cadmium-containing silver solders (common in HVAC, jewelry, dental) can release significant cadmium fume. Many operations are unaware their work triggers the standard. The plan includes the trigger procedure.
Medical removal protection
Elevated CdU, CdB, or β2-M triggers medical removal per 1910.1027(l)(11). The plan documents the removal procedure with the threshold criteria.
What you receive
- Cadmium Compliance Plan (Word .docx) — written program per (d)-(n)
- Initial exposure determination procedure (PEL: 5 µg/m³; Action Level: 2.5 µg/m³)
- Air monitoring schedule (initial + periodic + change-triggered)
- Methods of compliance — engineering & work practice controls hierarchy
- Respiratory protection program crosswalk (with 1910.134)
- Medical surveillance protocol (examination by or under the supervision of a licensed physician, blood/biological tests as applicable)
- Regulated area designation procedure (where exposures exceed the PEL)
- Housekeeping and hygiene procedures
- Employee training outline (annual refresher requirement)
- Recordkeeping requirements (exposure: 30 years; medical: employment + 30 years)
- Biomonitoring program (CdU ≤3 µg/g creatinine; CdB ≤5 µg/L; β2-M ≤300 µg/g creatinine)
- Medical removal trigger criteria
- Annual training matrix
How you get it
This document is written and reviewed against the standard it cites, and it is ready now. The download link is emailed as soon as your payment clears.
Revisions included — if something about your operation changes what the document should say, reply to the delivery email and we will amend it.
Who buys this
- NiCd battery manufacturing
- Cadmium electroplating
- Pigment manufacturing (cadmium-based pigments)
- Brazing operations with cadmium-containing filler
- Soldering operations with cadmium alloys
- Lead smelters (cadmium byproduct exposure)
Frequently asked
When does the cadmium standard apply?
1910.1027 (general industry) and 1926.1127 (construction) apply to any employer with employees exposed to cadmium in any form — pure cadmium, cadmium compounds, cadmium-containing alloys. PEL 5 µg/m³ TWA, AL 2.5 µg/m³. Common exposures: NiCd battery manufacturing, electroplating, pigment production, brazing with cadmium fillers, soldering with cadmium alloys, secondary lead smelters (cadmium is a common impurity).
What's β2-microglobulin and why is it tested?
β2-M is a small protein normally filtered and reabsorbed by the kidneys. When cadmium damages the proximal tubule, reabsorption fails and β2-M appears in urine. β2-M elevation is the EARLIEST clinical sign of cadmium-induced kidney damage — usually appearing years before traditional kidney function tests change. Under 29 CFR 1910.1027(l)(3)(ii) a β2-M result exceeding 300 µg/g creatinine triggers exposure reassessment and a medical examination. Mandatory removal requires β2-M above 750 µg/g creatinine (or CdU above 7, or CdB above 10) on both the initial and the examination monitoring, and in addition CdU above 3 or CdB above 5 — 29 CFR 1910.1027(l)(3)(iv)(C).
Is cadmium really a carcinogen?
Yes. IARC classifies cadmium and cadmium compounds as Group 1 (carcinogenic to humans) based on lung cancer evidence. NTP and EPA agree. OSHA's preamble to the cadmium standard documented the cancer risk. The medical surveillance and removal provisions reflect both the carcinogen risk and the kidney toxicity risk.
Does brazing with cadmium-containing solder trigger this?
Yes — and many small businesses don't realise it. Silver solders containing cadmium (typically 15-30% cadmium content) are still in use in HVAC, jewelry, dental, and specialty fabrication. The brazing fume can substantially exceed the PEL even for short-duration work. The plan includes the trigger procedure and recommends cadmium-free silver solder alternatives where feasible.
How does this differ between general industry and construction?
1910.1027 (general industry) and 1926.1127 (construction) have nearly identical PELs, action levels, exposure determination, and medical surveillance requirements. The main differences: regulated area requirements (1910.1027 specific; 1926.1127 modified for construction sites), hygiene facilities (1910.1027 has more stringent requirements; 1926.1127 allows portable alternatives), and methods of compliance (1926.1127 explicitly allows respirator-based compliance in some construction scenarios where engineering controls aren't feasible).